Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma. Twelve-year’s results of a phase II study

MLA

Serretta, Vincenzo, et al. Long-Term Outcome of Antiandrogen Monotherapy in Advanced Prostate Carcinoma. Twelve-Year’s Results of a Phase II Study. Jan. 2003. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3658..5b8fd73ee039668f0f514f8746a147c5&authtype=sso&custid=ns315887.

APA

Serretta, V., Dispensa, N., Pavone, C., Daricello, G., Allegro, R., & Pavone Macaluso, M. (2003). Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma. Twelve-year’s results of a phase II study.

Chicago

Serretta, Vincenzo, Nino Dispensa, Carlo Pavone, G Daricello, Rosalinda Allegro, and M. Pavone Macaluso. 2003. “Long-Term Outcome of Antiandrogen Monotherapy in Advanced Prostate Carcinoma. Twelve-Year’s Results of a Phase II Study,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3658..5b8fd73ee039668f0f514f8746a147c5&authtype=sso&custid=ns315887.